FGFR

Fibroblast growth factor receptor

FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins. Some of these receptors are involved in pathological conditions. A point mutation in FGFR3 can lead to achondroplasia. Five distinct membrane FGFR have been identified in vertebrates and all of them belong to the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). The fibroblast growth factor family constitutes one of the most important groups of paracrine factors that act during development. They are responsible for determining certain cells to become mesoderm, for the production of blood vessels, for limb outgrowth, and for the growth and differentiation of numerous cell types.

FGFR Inhibitors

(Z)-Orantinib

((Z)-SU6668; (Z)-TSU-68)

Cat. No.: HY-10517A

(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of **Flk1/KDR**, **PDGFRβ**, and **FGFR1**, with IC_{50}s of 2.1, 0.008, and 1.2 μM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

2,5-Dihydroxybenzoic acid

Cat. No.: HY-W001179

2,5-Dihydroxybenzoic acid is a derivative of benzoic and a powerful inhibitor of **fibroblast growth factors**.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

Alofanib

(RPT835)

Cat. No.: HY-17601

Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (**FGFR2**). Anticancer and antiangiogenic activity.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ASP5878

Cat. No.: HY-19983

ASP5878 is an oral active inhibitor of **FGFR 1, 2, 3, and 4**, with IC_{50} values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD4547

Cat. No.: HY-13330

AZD4547 is a potent inhibitor of the **FGFR** family with IC_{50}s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for **FGFR1**, **FGFR2**, **FGFR3**, and **FGFR4**, respectively.



Purity: 99.68%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

BLU9931

Cat. No.: HY-12823

BLU9931 is a potent, highly selective, and irreversible **fibroblast growth factor receptor 4 (FGFR4)** inhibitor with an IC_{50} of 3 nM and a K_d of 6 nM. BLU9931 has significant antitumor activity.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BO-264

Cat. No.: HY-135960

BO-264 is a highly potent and orally active **transforming acidic coiled-coil 3 (TACC3)** inhibitor with an IC_{50} of 188 nM and a K_d of 1.5 nM. BO-264 specifically blocks the function of **FGFR3-TACC3** fusion protein.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg, 250 mg

CH5183284

(Debio 1347)

Cat. No.: HY-19957

CH5183284 (Debio 1347) is an orally available and selective **FGFR** inhibitor with IC_{50}s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.



Purity: 99.73%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CP-547632

Cat. No.: HY-13302

CP-547632 is an orally active, ATP-competitive and potent **VEGFR-2** and **FGF** kinases inhibitor with IC_{50}s of 11 nM and 9 nM, respectively. CP-547632 is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 has antitumor efficacy.



Purity: >99.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CP-547632 hydrochloride

Cat. No.: HY-13302B

CP-547632 hydrochloride is an orally active, ATP-competitive and potent **VEGFR-2** and **FGF** kinases inhibitor with IC_{50}s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs).



Purity: 98.24%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CP-547632 TFA

Cat. No.: HY-13302C

CP-547632 TFA is an orally active, ATP-competitive and potent **VEGFR-2** and **FGF** kinases inhibitor with **IC_{50}**s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CPL304110

Cat. No.: HY-131908

CPL304110 is a potent, orally active and selective inhibitor of **fibroblast growth factor receptors FGFR (1-3)**, with **IC_{50}** values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Derazantinib

(ARQ-087)

Cat. No.: HY-19981

Derazantinib (ARQ-087) is an ATP competitive tyrosine kinase inhibitor; exhibits potent activity against **FGFR1-3** chondrocytes with **IC_{50}**s of 4.5, 1.8, and 4.5 nM, respectively.



Purity: 99.18%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Derazantinib Racemate

(ARQ-087 Racemate)

Cat. No.: HY-19981A

Derazantinib Racemate (ARQ-087 Racemate) is the racemate of Derazantinib; Derazantinib is a potent inhibitor of FGFR1-3.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg

Dovitinib

(CHIR-258; TKI258)

Cat. No.: HY-50905

Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with **IC_{50}**s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: 97.18%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Dovitinib lactate

(CHIR-258 lactate; TKI-258 lactate)

Cat. No.: HY-10207

Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with **IC_{50}**s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: 99.96%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

ENMD-2076

Cat. No.: HY-10987A

ENMD-2076 is a multi-targeted kinase inhibitor with **IC_{50}**s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ENMD-2076 Tartrate

Cat. No.: HY-10987

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with **IC_{50}**s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 98.59%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

EOC317

(ACTB-1003)

Cat. No.: HY-16025

EOC317 (ACTB-1003) is an oral kinase inhibitor with **IC_{50}**s of 6, 2 and 4 nM for **FGFR1**, **VEGFR2** and **Tie-2**.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Erdafitinib

(JNJ-42756493)

Cat. No.: HY-18708

Erdafitinib (JNJ-42756493) is a potent and orally available **FGFR** family inhibitor; inhibits FGFR1/2/3/4 with **IC_{50}**s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.



Purity: 99.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ferulic acid

(Coniferic acid) Cat. No.: HY-N0060

Ferulic acid is a novel fibroblast growth factor receptor 1 (**FGFR1**) inhibitor with IC_{50}s of 3.78 and 12.5 μM for **FGFR1** and **FGFR2**, respectively.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Ferulic acid sodium

(Coniferic acid sodium) Cat. No.: HY-N0060A

Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (**FGFR1**) inhibitor with IC_{50}s of 3.78 and 12.5 μM for **FGFR1** and **FGFR2**, respectively.



Purity: 99.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g, 5 g

FGFR1/DDR2 inhibitor 1

Cat. No.: HY-114311

FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of **fibroblast growth factor receptor 1 (FGFR1)** and **discoindin domain receptor 2 (DDR2)**, with IC_{50} values of 31.1 nM and 3.2 nM, respectively. Antitumor activity.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FGFR4-IN-1

Cat. No.: HY-100631

FGFR4-IN-1 is a potent inhibiotr of **FGFR4** with IC_{50} of 0.7 nM.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FIIN-2

Cat. No.: HY-18602

FIIN-2 is an irreversible inhibitor of **FGFR** with an IC_{50} of 3.1, 4.3, 27, and 45 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

FIIN-3

Cat. No.: HY-18603

FIIN-3 is an irreversible inhibitor of **FGFR** with an IC_{50} of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Fisogatinib

(BLU-554) Cat. No.: HY-100492

Fisogatinib (BLU-554) is a potent, highly selective and orally active **fibroblast growth factor receptor 4 (FGFR4)** inhibitor with an IC_{50} of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on **FGFR4** signalling.



Purity: 99.84%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Formononetin

(Biochanin B; Flavosil; Formononetol) Cat. No.: HY-N0183

Formononetin (Formononetol; Flavosil) is a bioactive component extracted from the red clover; inhibits the proliferation of DU-145/PC-3 cells in a dose-dependent manner.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Futibatinib

(TAS-120) Cat. No.: HY-100818

Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible **FGFR** inhibitor, with IC_{50}s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively.



Purity: 98.80%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Gandotinib

(LY2784544) Cat. No.: HY-13034

Gandotinib (LY2784544) is a potent **JAK2** inhibitor with IC_{50} of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC_{50} of 4, 25, 32, 44, and 95 nM.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Heparan Sulfate

Cat. No.: HY-101916

Heparan sulfate, a complex and linear polysaccharide, exists as part of glycoproteins named heparan sulfate proteoglycans, which are expressed abundantly on the cell surface and in the extracellular matrix.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Infigratinib

(BGJ-398; NVP-BGJ398)

Cat. No.: HY-13311

Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the **FGFR** family with **IC_{50}**s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for **FGFR1**, **FGFR2**, **FGFR3**, and **FGFR4**, respectively.



Purity: 99.55%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Infigratinib phosphate

(BGJ-398 phosphate; NVP-BGJ398 phosphate)

Cat. No.: HY-13311A

Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the **FGFR** family with **IC_{50}** of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for **FGFR1**, **FGFR2**, **FGFR3**, and **FGFR4**, respectively.



Purity: 97.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

KW-2449

Cat. No.: HY-10339

KW-2449 is a multi-targeted kinase inhibitor of **FLT3**, **ABL**, **ABL^{T315I}** and **Aurora kinase** with **IC_{50}**s of 6.6, 14, 4 and 48 nM, respectively.



Purity: 99.85%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib

(E7080)

Cat. No.: HY-10981

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib mesylate

(E7080 mesylate)

Cat. No.: HY-10981A

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lucitanib

(E-3810)

Cat. No.: HY-15391

Lucitanib (E-3810) is a novel dual inhibitor of **VEGFR** and **FGFR**, potently and selectively inhibits **VEGFR1**, **VEGFR2**, **VEGFR3**, **FGFR1** and **FGFR2** with **IC_{50}**s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.



Purity: 99.32%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

LY2874455

Cat. No.: HY-13304

LY2874455 is a **pan-FGFR** inhibitor with **IC_{50}**s of 2.8, 2.6, 6.4, 6 nM for **FGFR1**, **FGFR2**, **FGFR3**, **FGFR4**, respectively.



Purity: 98.06%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Masitinib

(AB1010)

Cat. No.: HY-10209

Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (**IC_{50}**=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (**IC_{50}**s=540/800 nM), **Lyn** (**IC_{50}**= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Masitinib mesylate

(AB-1010 mesylate)

Cat. No.: HY-10209A

Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (**IC_{50}**=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (**IC_{50}**s=540/800 nM), **Lyn** (**IC_{50}**= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Nintedanib

(BIBF 1120) Cat. No.: HY-50904

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Nintedanib esylate

(BIBF 1120 esylate) Cat. No.: HY-11106

Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

ODM-203

Cat. No.: HY-119367

ODM-203 is a potent **FGFR** and **VEGFR** families inhibitor with IC_{50}s of 11, 16, 6, 35 nM towards recombinant FGFR1, FGFR2, FGFR3 and FGFR4 as well as 26, 9, 5 nM towards VEGFR1, VEGFR2 and VEGFR3, respectively. ODM-203 exhibits strong anti-tumor activity and induces anti-tumor immunity.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Orantinib

(SU6668; TSU-68) Cat. No.: HY-10517

Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with K_is of 2.1 μM, 8 nM and 1.2 μM for **Flt-1**, **PDGFRβ** and **FGFR1**, respectively.



Purity: 98.80%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Pazopanib

(GW786034) Cat. No.: HY-10208

Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with IC_{50}s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pazopanib Hydrochloride

(GW786034 (Hydrochloride)) Cat. No.: HY-12009

Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with an IC_{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

PD-089828

Cat. No.: HY-112345

PD-089828 is an ATP competitive inhibitor of **FGFR-1**, **PDGFR-β** and **EGFR** (IC_{50}s=0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of **c-Src** tyrosine kinase (IC_{50}=0.18 μM). PD-089828 also inhibits **MAPK** with an IC_{50} of 7.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD-161570

Cat. No.: HY-100434

PD-161570 is a potent and ATP-competitive **human FGF-1 receptor** inhibitor with an IC_{50} of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the **PDGFR**, **EGFR** and **c-Src tyrosine kinases** with IC_{50} values of 310 nM, 240 nM, and 44 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

PD-166866

Cat. No.: HY-101296

PD166866 is a selective **FGFR1** tyrosine kinase inhibitor with an IC_{50} of 52.4 nM.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PD173074

Cat. No.: HY-10321

PD173074 is a potent **FGFR1** inhibitor with an IC_{50} of 25 nM and also inhibits **VEGFR2** with an IC_{50} of 100-200 nM, showing 1000-fold selectivity for FGFR1 over PDGFR and c-Src.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Pemigatinib

(INCB054828) Cat. No.: HY-109099

Pemigatinib (INCB054828) is an orally active, selective **FGFR** inhibitor with IC_{50}s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma.



Purity: 99.88%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 500 mg

PF 477736

(PF 00477736) Cat. No.: HY-10032

PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of **Chk1**, with a K_i of 0.49 nM, it is also a **Chk2** inhibitor, with a K_i of 47 nM.



Purity: 99.21%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Ponatinib

(AP24534) Cat. No.: HY-12047

Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 99.13%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PP58

Cat. No.: HY-18622

PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits **PDGFR**, **FGFR** and **Src** family activities with nanomolar IC_{50} values.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PRN1371

Cat. No.: HY-101768

PRN1371 is a highly selective and potent **FGFR1-4** and **CSF1R** inhibitor with IC_{50}s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively.



Purity: 99.72%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

R1530

Cat. No.: HY-13737

R1530 is a highly potent, orally bioavailable, dual-acting **mitosis/angiogenesis** inhibitor, with antitumor and anti-angiogenic activity. R1530 is a multikinase inhibitor which binds to 31 kinases with K_ds of <500 nM.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

Roblitinib

(FGF-401) Cat. No.: HY-101568

Roblitinib (FGF-401; Compound Example 83) is a highly selective and potent **FGFR4** inhibitor with an IC_{50} of 1.9 nM. Roblitinib has antitumor activity.



Purity: 99.33%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Rogaratinib

(BAY1163877) Cat. No.: HY-100019

Rogaratinib is a potent and selective **fibroblast growth factor receptor** (**FGFR**) inhibitor.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

S49076

Cat. No.: HY-12965

S49076 is a novel, potent inhibitor of **MET**, **AXL/MER**, and **FGFR1/2/3** with IC_{50} values below 20 nM.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

SKLB610

Cat. No.: HY-18199

SKLB610 is a **VEGFR** inhibitor with potent anti-tumor activity.



Purity: 99.23%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SSR128129E

(SSR)

Cat. No.: HY-15599

SSR128129E is an orally available and allosteric **FGFR** inhibitor with an IC_{50} of 1.9 μM for FGFR1.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SU 5402

Cat. No.: HY-10407

SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC_{50} of 20 nM, 30 nM, and 510 nM for **VEGFR2**, **FGFR1**, and **PDGFRβ**, respectively.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sulfatinib

(HMPL-012)

Cat. No.: HY-12297

Sulfatinib (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against **VEGFR1/2/3**, **FGFR1** and **CSF1R** with IC_{50}s of in a range of 1 to 24 nM.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

SUN11602

Cat. No.: HY-101493

SUN11602 is a novel aniline compound with basic fibroblast growth factor-like activity.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TG 100572 Hydrochloride

Cat. No.: HY-10185

TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

TG 100801

Cat. No.: HY-10186

TG 100801 is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: 98.60%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg

Tyrosine kinase-IN-1

Cat. No.: HY-100315

Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 4, 20, 4, 2 nM for **KDR**, **Flt-1**, **FGFR1** and **PDGFRα**, respectively.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg